Stocks · News reference
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per share from the same
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today
Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be webcast and available for 30 days. The company continues to focus on organic growth of its commercial portfolio, plasma collection operations, and pursuing M&A opportunities.
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.